A Phase 2, Randomized, Multicenter, Double-Blind, Active and Vehicle Controlled Parallel-group Study Evaluating the Efficacy, Safety, and Tolerability of Products S6G5T-3 and S6G5T-1 for the Treatment of Acne Vulgaris for 12 Weeks

Trial Profile

A Phase 2, Randomized, Multicenter, Double-Blind, Active and Vehicle Controlled Parallel-group Study Evaluating the Efficacy, Safety, and Tolerability of Products S6G5T-3 and S6G5T-1 for the Treatment of Acne Vulgaris for 12 Weeks

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Oct 2017

At a glance

  • Drugs Benzoyl peroxide/tretinoin (Primary)
  • Indications Acne vulgaris
  • Focus Therapeutic Use
  • Sponsors Sol-Gel Technologies
  • Most Recent Events

    • 03 Oct 2017 Status changed from active, no longer recruiting to completed.
    • 20 Jul 2017 Results published in a Sol-Gel Technologies media release
    • 20 Jul 2017 Primary endpoint (Absolute change in lesion count (separately for inflammatory and non-inflammatory)) has been met according to a Sol-Gel Technologies media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top